Olaparib-Resistant BRCA2(MUT) Ovarian Cancer Cells with Restored BRCA2 Abrogate Olaparib-Induced DNA Damage and G2/M Arrest Controlled by the ATR/CHK1 Pathway for Survival

The PARP inhibitor (PARPi) olaparib is currently the drug of choice for serous ovarian cancer (OC), especially in patients with homologous recombination (HR) repair deficiency associated with deleterious BRCA1/2 mutations. Unfortunately, OC patients who fail to respond to PARPi or relapse after trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Biegała, Łukasz, Gajek, Arkadiusz, Marczak, Agnieszka, Rogalska, Aneta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093185/
https://www.ncbi.nlm.nih.gov/pubmed/37048111
http://dx.doi.org/10.3390/cells12071038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093185/
https://www.ncbi.nlm.nih.gov/pubmed/37048111
http://dx.doi.org/10.3390/cells12071038

Ejemplares similares